PCOLE-1 (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-PCOLE1
In stock
- SKU
- REC-PCOLE1
Target Overview
PCOLE-1 (Recombinant) is the human Procollagen C-endopeptidase enhancer 1 (PCPE-1), encoded by the PCOLCE gene (UniProt Q15113), produced by transient expression in HEK293 cells. The full-length human PCOLCE sequence spans 449 amino acids; the secreted mature form lacks the signal peptide and is recovered from conditioned medium under native-like glycosylation conditions that HEK293 expression affords — an important consideration for a secreted extracellular matrix (ECM) glycoprotein whose binding interactions are conformation-sensitive. PCPE-1 functions by binding to the C-terminal propeptide of fibrillar procollagens (most characterized for type I procollagen) and enhancing the proteolytic activity of procollagen C-proteinase (BMP-1/tolloid family metalloproteinases). It does not itself possess enzymatic activity; rather, it acts as a non-catalytic enhancer that accelerates the rate-limiting C-propeptide cleavage step of collagen maturation in the extracellular space. Researchers use this recombinant in several experimental contexts: (1) activity enhancement assays, where PCPE-1 is titrated alongside BMP-1 against a procollagen substrate to measure fold-increase in C-propeptide processing; (2) binding/interaction studies using surface plasmon resonance (SPR) or biolayer interferometry (BLI) to characterise affinity for procollagen C-propeptide; (3) inhibitor competition assays, where small-molecule or peptide inhibitors of the PCPE-1/BMP-1 axis are ranked by their ability to displace PCPE-1 from its substrate; and (4) antibody validation, where the recombinant serves as a positive control antigen alongside the matched Triple Point Biologics antibody (RP-PCOLE1), which has been validated for Western blot applications. HEK293-derived material is preferred over bacterial expression for this target because correct disulfide bonding within the CUB and NTR domains is required for functional activity.
Background
Applications
- Procollagen C-proteinase enhancement assay: titration of PCPE-1 alongside BMP-1 against type I procollagen substrate to quantify fold-increase in C-propeptide cleavage
- BMP-1/tolloid metalloproteinase inhibitor competition assay: ranking small-molecule or peptide inhibitors by displacement of PCPE-1 from procollagen C-propeptide
- Surface plasmon resonance (SPR) or biolayer interferometry (BLI) binding kinetics: determination of KD for PCPE-1 interaction with procollagen C-propeptide
- Antibody validation positive control: use as defined antigen in Western blot and IHC validation alongside matched antibody RP-PCOLE1
- ELISA standard curve: recombinant PCPE-1 as calibrator for sandwich ELISA quantification of endogenous PCPE-1 in conditioned media or tissue lysates
- Fibrosis model ECM assay: supplementing cell-free or cell-based collagen processing systems to assess PCPE-1 contribution to fibril assembly kinetics
- PCPE-1 vs. PCPE-2 functional comparison: parallel assay format to distinguish enhancer activity and substrate selectivity between the two paralogs
References
- Sorci-Thomas MG et al. PCPE1 and PCPE2: When Sequence Similarity Masks Functional Diversity. Arterioscler Thromb Vasc Biol. 2026. doi:10.1161/ATVBAHA.126.324421. PMID: 41953976.
- Zhang Z et al. Dual role of fibroblasts in fibrous scar formation after spinal cord injury: Single-cell sequencing and experimental verification. Neural Regen Res. 2026. doi:10.4103/NRR.NRR-D-25-01445. PMID: 42199129.
- Liu X et al. Identification of Novel Disease-Modifying Agents for Pelvic Organ Prolapse by Systematic Druggable Genome-Wide Mendelian Randomization. Int J Womens Health. 2025. doi:10.2147/IJWH.S525908. PMID: 41089176.
- Huang W et al. Identification and single-cell analysis of prognostic genes related to mitochondrial and neutrophil extracellular traps in bladder cancer. Sci Rep. 2025. doi:10.1038/s41598-025-10413-3. PMID: 40615671.
- Liu L et al. Prognostic integration of tumor microenvironment and parthanatos-related genes in gastric cancer: a machine learning-driven risk model and immune landscape profiling. Front Immunol. 2026. doi:10.3389/fimmu.2026.1636331. PMID: 41798945.
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Subcellular localization not yet annotated |
Frequently Asked Questions
What is the expected molecular weight of PCOLE-1 (Recombinant) on SDS-PAGE and Western blot?
The full-length PCOLCE-encoded protein is 449 amino acids (predicted unglycosylated MW ~50 kDa), but because this recombinant is expressed in HEK293 cells under native-like glycosylation conditions, the observed band on reducing SDS-PAGE typically migrates at approximately 55–65 kDa. The shift reflects N-linked glycosylation characteristic of the secreted, mature ECM form. Expect a diffuse or slightly smeared band rather than a sharp single band — this is normal for glycoproteins and is not indicative of degradation. Deglycosylation with PNGase F collapses the band to ~50 kDa.
Is PCOLE-1 (Recombinant) the full-length protein or the mature secreted form lacking the signal peptide?
This recombinant corresponds to the mature secreted form of human PCPE-1 (UniProt Q15113). The N-terminal signal peptide is cleaved co-translationally during HEK293 expression, so what is recovered from conditioned medium is the processed extracellular form — the biologically relevant species for collagen maturation studies. No additional prodomain processing is required. The two CUB domains and the NTR domain are intact, preserving the conformation-sensitive binding interface with the C-terminal propeptide of fibrillar procollagens.
Does PCOLE-1 (Recombinant) have enzymatic activity itself, or does it require BMP-1/tolloid for collagen C-propeptide cleavage?
PCPE-1 is a non-catalytic enhancer — it has no intrinsic proteinase activity. Its function is to bind the C-terminal propeptide of fibrillar procollagens (best characterized for type I procollagen) and accelerate cleavage by BMP-1/tolloid family metalloproteinases. In activity assays, PCOLE-1 (Recombinant) should be used alongside a source of active BMP-1 or mTLD. Without the metalloproteinase, you will not observe substrate processing regardless of PCPE-1 concentration. This recombinant is validated as an enhancer, not a standalone proteinase.
What activity assay can I use to measure PCOLE-1 (Recombinant) enhancement of procollagen C-proteinase, and what substrate should I use?
The standard assay uses recombinant type I procollagen C-propeptide (pCP) or mini-procollagen substrates incubated with a titrated amount of active BMP-1 in the presence or absence of PCOLE-1 (Recombinant). Cleavage is monitored by SDS-PAGE densitometry or fluorescent-tagged substrate variants. A typical starting point is 50–200 ng/mL PCOLE-1 alongside 10–50 ng/mL BMP-1 in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂ at 37°C for 1–4 hours. Enhancement is expressed as fold-increase in cleavage rate relative to BMP-1 alone. Titrate PCPE-1 to establish dose-dependence before committing to a fixed concentration.
What buffer conditions are optimal for PCOLE-1 (Recombinant) activity assays and protein–protein interaction studies?
The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — is compatible with most collagen maturation assays and can be used directly. For SPR or pull-down binding assays measuring PCPE-1 interaction with procollagen C-propeptide, reduce glycerol to ≤1% by diluting into assay buffer immediately before use. CaCl₂ at 1–5 mM is recommended when BMP-1 is a binding partner, as it is required for metalloproteinase activity. Avoid EDTA or EGTA in functional assays. pH should remain between 7.2 and 7.8; PCPE-1 binding interactions are conformation-sensitive and activity drops sharply below pH 6.8.
What starting concentration of PCOLE-1 (Recombinant) is recommended for co-immunoprecipitation or pull-down with BMP-1?
For co-IP or GST/His-tag pull-down experiments, a practical starting range is 0.5–2 µg PCOLE-1 (Recombinant) per reaction. Because PCPE-1 binds the procollagen C-propeptide non-covalently with moderate affinity, keeping protein concentrations in the 100–500 nM range during incubation improves complex recovery. Include 0.05% Tween-20 and 1 mg/mL BSA in binding buffer to reduce non-specific adsorption. Verify the pulled-down PCPE-1 by Western blot using our matched antibody RP-PCOLE1, which is validated for WB and provides a reliable readout at these loading amounts.
Can I use PCOLE-1 (Recombinant) as a positive control for Western blot with the matched antibody RP-PCOLE1?
Yes — PCOLE-1 (Recombinant) and antibody RP-PCOLE1 are produced from the same lab and are guaranteed compatible for Western blot positive control applications. Load 25–100 ng of recombinant protein per lane on a 10–12% SDS-PAGE gel under reducing conditions. The antibody at 1:1,000–1:2,000 dilution (primary, overnight 4°C) detects a band at ~55–65 kDa, consistent with the glycosylated mature form. This serves as a reliable size marker and signal calibrator when running cell lysates or tissue extracts alongside. Product page and protocol for RP-PCOLE1 are at /anti-pcole-1-rabbit-polyclonal-antibody.
How should I handle, dilute, and store PCOLE-1 (Recombinant) to maintain activity over multiple experiments?
PCOLE-1 (Recombinant) is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol as single-use aliquots. Store at -20°C; purity is >95% by SDS-PAGE and endotoxin is <0.1 EU/µg by LAL. Avoid repeated freeze-thaw — each cycle risks glycoprotein aggregation and loss of the native conformation required for procollagen C-propeptide binding. For working dilutions, prepare fresh in assay buffer the day of the experiment and keep on ice. If you anticipate multiple uses within a week, a single thaw followed by storage at 4°C for up to 5 days is acceptable; beyond that, re-aliquot before first thaw.
Validation imagery coming soon
Western blot validation figures for REC-PCOLE1 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.